Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More
WANBURY ACTAVIS |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
WANBURY Mar-23 |
ACTAVIS Dec-18 |
WANBURY/ ACTAVIS |
5-Yr Chart Click to enlarge
|
||
High | Rs | 90 | 16,126 | - | |
Low | Rs | 33 | 10,818 | - | |
Sales per share (Unadj.) | Rs | 152.8 | 3,955.8 | - | |
Earnings per share (Unadj.) | Rs | -3.2 | -1,274.2 | - | |
Cash flow per share (Unadj.) | Rs | 0.6 | 416.9 | - | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Avg Dividend yield | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | -10.5 | 16,315.7 | - | |
Shares outstanding (eoy) | m | 32.71 | 332.60 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 0.4 | 3.4 | 11.8% | |
Avg P/E ratio | x | -19.3 | -10.6 | 182.3% | |
P/CF ratio (eoy) | x | 100.8 | 32.3 | 311.8% | |
Price / Book Value ratio | x | -5.8 | 0.8 | -704.6% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 2,004 | 4,480,758 | 0.0% | |
No. of employees | `000 | NA | 16.9 | 0.0% | |
Total wages/salary | Rs m | 810 | 0 | - | |
Avg. sales/employee | Rs Th | 0 | 77,851.4 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | -25,076.0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 4,996 | 1,315,689 | 0.4% | |
Other income | Rs m | 10 | 25,160 | 0.0% | |
Total revenues | Rs m | 5,007 | 1,340,849 | 0.4% | |
Gross profit | Rs m | 225 | 34,478 | 0.7% | |
Depreciation | Rs m | 124 | 562,428 | 0.0% | |
Interest | Rs m | 214 | 75,923 | 0.3% | |
Profit before tax | Rs m | -103 | -578,713 | 0.0% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 147,595 | 0.0% | |
Tax | Rs m | 1 | -7,334 | -0.0% | |
Profit after tax | Rs m | -104 | -423,784 | 0.0% | |
Gross profit margin | % | 4.5 | 2.6 | 171.7% | |
Effective tax rate | % | -1.1 | 1.3 | -83.6% | |
Net profit margin | % | -2.1 | -32.2 | 6.5% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 1,222 | 539,627 | 0.2% | |
Current liabilities | Rs m | 3,204 | 477,372 | 0.7% | |
Net working cap to sales | % | -39.7 | 4.7 | -838.4% | |
Current ratio | x | 0.4 | 1.1 | 33.7% | |
Inventory Days | Days | 4 | 20 | 20.6% | |
Debtors Days | Days | 497 | 66 | 748.9% | |
Net fixed assets | Rs m | 1,742 | 148,929 | 1.2% | |
Share capital | Rs m | 327 | 0 | - | |
Net worth | Rs m | -344 | 5,426,601 | -0.0% | |
Long term debt | Rs m | 0 | 1,910,903 | 0.0% | |
Total assets | Rs m | 2,984 | 8,483,012 | 0.0% | |
Interest coverage | x | 0.5 | -6.6 | -7.8% | |
Debt to equity ratio | x | 0 | 0.4 | -0.0% | |
Sales to assets ratio | x | 1.7 | 0.2 | 1,079.7% | |
Return on assets | % | 3.7 | -4.1 | -89.9% | |
Return on equity | % | 30.2 | -7.8 | -386.4% | |
Return on capital | % | -32.2 | -4.8 | 666.1% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 198 | 470,046 | 0.0% | |
From Investments | Rs m | -88 | 258,229 | -0.0% | |
From Financial Activity | Rs m | -320 | -806,740 | 0.0% | |
Net Cashflow | Rs m | -210 | -78,073 | 0.3% |
Compare WANBURY With: MYLAN (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Compare WANBURY With: GUJ.TERC LAB BLISS GVS PHARMA ZANDU REALTY DENIS CHEM LAB ADLINE CHEM LAB
Indian share markets continued the momentum as the session progressed and ended the higher.